Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$125.85

5.45 (4.53%)

08:04
08/25/17
08/25
08:04
08/25/17
08:04

Tesaro announces nine data presentations at ESMO meeting

TESARO announced that data from nine abstracts will be presented at the 2017 European Society for Medical Oncology annual meeting, September 8 to September 12, 2017, in Madrid. "We are excited that a wealth of data from the landmark ENGOT-OV16/NOVA trial will be presented at this year's ESMO Annual Meeting," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Patient-reported quality of life data for patients treated with niraparib versus placebo will be featured in an oral presentation and the results of two post-hoc analyses, the observed exposure-response relationship of niraparib in gBRCAmut and non-gBRCAmut patients, and the safety and efficacy of niraparib in elderly patients, will be subjects for poster discussions. In addition, data from the Phase 1/2 trial of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent platinum-resistant ovarian cancer will be highlighted in a poster discussion. Finally, a poster will be presented detailing results from the Phase 1 study of TSR-042, our anti-PD-1 antibody."

  • 06

    Sep

  • 06

    Sep

  • 08

    Sep

  • 25

    Oct

TSRO Tesaro
$125.85

5.45 (4.53%)

08/17/17
BOFA
08/17/17
NO CHANGE
Target $59
BOFA
Tesaro and Clovis at BofA/Merrill
BofA/Merrill said it already assumed that the maintenance Ovarian cancer PARP market would be shared between Tesaro (TSRO), Clovis (CLVS), and AstraZeneca (AZN) and differences, combined with more nuanced differentiators in safety and dosing justify multiple participants. The firm's analyst reiterates Buy ratings on both Clovis and Tesaro and notes both have demonstrated strong initial uptake.
08/18/17
SBSH
08/18/17
NO CHANGE
Target $216
SBSH
Buy
Citi sees advantage for Tesaro despite broad Lynparza label
Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's (AZN) Lynparza increases competition for Tesaro (TSRO). Lynparza got a broad label in all ovarian cancer patients, which Karnauskas says she was not modeling for. The analyst suspects Clovis Oncology (CLVS) could also get a similar broad label. Nonetheless, she believes that with "better clinical data, better value, and dosing convenience," Tesaro's Zejula has a potential marketing advantage. Oncologic drugs with the best outcomes data eventually emerge market winners, Karnauskas tells investors in a research note. The analyst keeps a Buy rating on Tesaro with a $216 price target. The shares closed yesterday down $3.94 to $109.05.
08/18/17
LEER
08/18/17
NO CHANGE
Target $107
LEER
Outperform
Clovis price target lowered to $107 from $115 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Clovis Oncology (CLVS) to $107 after competitor AstraZeneca (AZN) received a broad label for PARP inhibitor Lynparza as maintenance treatment following second line ovarian cancer therapy regardless of BRCA status. His new target reflects a three-way market split among Clovis' Rubraca, Tesaro's (TSRO) Zejula and Lynparza in second line ovarian cancer maintenance. The analyst, however, believes Clovis remains attractively valued and he keeps an Outperform rating on the shares.
08/18/17
FBCO
08/18/17
NO CHANGE
Target $190
FBCO
Outperform
Tesaro, Clovis shares reflect very little M&A value, says Credit Suisse
Credit Suisse analyst Alethia Young believes AstraZeneca's (AZN) broad label news yesterday for Lynparza likely lifted an overhang for both Tesaro (TSRO) and Clovis Oncology (CLVS). Shares of both Tesaro and Clovis are reflecting "very little to no M&A value" at current levels, Young tells investors in a research note. She lowered her price target for Tesaro to $190 from $198 and keeps an Outperform rating on the name.

TODAY'S FREE FLY STORIES

TYL

Tyler Technologies

$179.58

0.07 (0.04%)

05:21
10/17/17
10/17
05:21
10/17/17
05:21
Downgrade
Tyler Technologies rating change  »

Tyler Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ICUI

ICU Medical

$188.40

0.9 (0.48%)

05:20
10/17/17
10/17
05:20
10/17/17
05:20
Initiation
ICU Medical initiated  »

ICU Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

NFLX

Netflix

$202.68

3.19 (1.60%)

05:17
10/17/17
10/17
05:17
10/17/17
05:17
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

EQT

EQT Corporation

$62.56

-0.45 (-0.71%)

, RICE

Rice Energy

$27.32

-0.2 (-0.73%)

05:17
10/17/17
10/17
05:17
10/17/17
05:17
Hot Stocks
EQT Corporation reiterates benefits of pending acquisition of Rice Energy »

EQT Corporation (EQT),…

EQT

EQT Corporation

$62.56

-0.45 (-0.71%)

RICE

Rice Energy

$27.32

-0.2 (-0.73%)

EQGP

EQT GP

$29.71

-0.53 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 14

    Nov

  • 15

    May

  • 16

    May

NFLX

Netflix

$202.68

3.19 (1.60%)

05:12
10/17/17
10/17
05:12
10/17/17
05:12
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CMC

Commercial Metals

$20.50

-0.28 (-1.35%)

, GGB

Gerdau

$3.57

-0.01 (-0.28%)

05:11
10/17/17
10/17
05:11
10/17/17
05:11
Upgrade
Commercial Metals, Gerdau rating change  »

Commercial Metals…

CMC

Commercial Metals

$20.50

-0.28 (-1.35%)

GGB

Gerdau

$3.57

-0.01 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SECO

Seeco Holding

$8.30

0.14 (1.72%)

05:07
10/17/17
10/17
05:07
10/17/17
05:07
Initiation
Seeco Holding initiated  »

Seeco Holding initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$198.41

-7.11 (-3.46%)

05:06
10/17/17
10/17
05:06
10/17/17
05:06
Recommendations
Allergan analyst commentary  »

Allergan price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

EV

Eaton Vance

$51.10

0.03 (0.06%)

05:02
10/17/17
10/17
05:02
10/17/17
05:02
Initiation
Eaton Vance initiated  »

Eaton Vance initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$31.48

0.2 (0.64%)

05:02
10/17/17
10/17
05:02
10/17/17
05:02
Initiation
Federated Investors initiated  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

JHG

Janus Henderson Group

$35.22

-0.08 (-0.23%)

05:01
10/17/17
10/17
05:01
10/17/17
05:01
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$37.63

-1.11 (-2.87%)

05:01
10/17/17
10/17
05:01
10/17/17
05:01
Initiation
Legg Mason initiated  »

Legg Mason initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WETF

WisdomTree

$11.00

0.01 (0.09%)

05:00
10/17/17
10/17
05:00
10/17/17
05:00
Initiation
WisdomTree initiated  »

WisdomTree initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.27

0.52 (3.53%)

04:59
10/17/17
10/17
04:59
10/17/17
04:59
Downgrade
Freeport McMoRan rating change  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ERJ

Embraer

$21.42

-0.63 (-2.86%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

04:56
10/17/17
10/17
04:56
10/17/17
04:56
Downgrade
Embraer, Airbus rating change  »

Embraer downgraded to…

ERJ

Embraer

$21.42

-0.63 (-2.86%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$114.58

0.72 (0.63%)

, CSOD

Cornerstone OnDemand

$39.02

0.02 (0.05%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Stephens human capital management team holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$114.58

0.72 (0.63%)

CSOD

Cornerstone OnDemand

$39.02

0.02 (0.05%)

MSFT

Microsoft

$77.65

0.16 (0.21%)

ORCL

Oracle

$48.86

0.25 (0.51%)

PAYC

Paycom

$78.99

-0.9 (-1.13%)

PCTY

Paylocity

$50.08

0.17 (0.34%)

SAP

SAP

$111.84

-0.88 (-0.78%)

ULTI

Ultimate Software

$194.45

-3.47 (-1.75%)

WDAY

Workday

$107.23

-2.13 (-1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 05

    Nov

  • 08

    Nov

  • 15

    Nov

WES

Western Gas Partners

$50.92

-0.38 (-0.74%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Western Gas Partners to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Stephens food & agribusiness analyst holds an analyst/industry conference call »

Food & Agribusiness…

SFNC

Simmons First National

$58.90

0.45 (0.77%)

, OKSB

Southwest Bancorp

$28.05

0.15 (0.54%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Southwest Bancorp to host special shareholder meeting »

Special Shareholder…

SFNC

Simmons First National

$58.90

0.45 (0.77%)

OKSB

Southwest Bancorp

$28.05

0.15 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 23

    Oct

CLSD

Clearside Biomedical

$7.77

0.03 (0.39%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Clearside Biomedical management to meet with JMP Securities »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AKR

Acadia Realty Trust

$30.26

-0.2 (-0.66%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Acadia Realty Trust management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 03

    Nov

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Citigroup to hold a conference »

9th Annual Australian…

GSM

Ferroglobe

$14.56

0.39 (2.75%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Ferroglobe to hold investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 14

    Nov

  • 15

    Nov

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Senate Banking, Housing & Urban Affairs Committee to hold a hearing »

The Committee holds a…

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Senate Health, Ed, Labor & Pensions Committee holds a hearing »

The Committee holds a…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.